An interventional phase I clinical trial of zanidatamab (NCT02892123) conducted in patients with locally advanced (unresectable) and/or metastatic HER2-expressing, KRAS wild-type CRC showed a promising clinical response with 38% ORR [43]. Here, KRAS is linked to colorectal carcinoma.